<DOC>
	<DOCNO>NCT01015118</DOCNO>
	<brief_summary>The trial perform evaluate BIBF 1120 combination paclitaxel carboplatin effective placebo combination paclitaxel carboplatin first-line treatment patient advanced ovarian cancer . Safety information BIBF1120/paclitaxel/carboplatin obtain .</brief_summary>
	<brief_title>LUME-Ovar 1 : Nintedanib ( BIBF 1120 ) Placebo Combination With Paclitaxel Carboplatin First Line Treatment Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : first diagnosis histologically confirm epithelial ovarian cancer , fallopian tube primary peritoneal cancer International Federation Gynecology Obstetrics ( FIGO ) Stages IIB IV female , age 18 year old life expectancy least 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 prior surgery , define either ( ) debulking surgery maximum surgical effort cytoreduction goal residual disease ( b ) biopsy limited surgery patient stage IV disease surgical debulking consider appropriate , diagnosis confirm histology surgery plan prior disease progression ( include interval debulking surgery ) patient give write informed consent must consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) local legislation plan application first dose chemotherapy wound healing , later 10 week surgery Exclusion criterion : histologic diagnosis benign borderline tumour malignant tumour nonepithelial origin ovary , fallopian tube peritoneum plan surgery within 124 week randomisation trial , include interval debulking surgery clinically relevant nonhealing wound , ulcer bone fracture clinical symptom sign gastrointestinal obstruction require parenteral nutrition hydration brain metastasis preexist sensory motor neuropathy Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 high , except due trauma history major thromboembolic event know inherit acquire bleed disorder significant cardiovascular disease clinically relevant pericardial effusion history cerebral vascular accident , transient ischemic attack subarachnoid haemorrhage within past 6 month inadequate safety laboratory value serious infection particular require systemic antibiotic ( antimicrobial , antifungal ) antiviral therapy , include Hepatitis B , Hepatitis C , Human Immunodeficiency Virus ( HIV ) poorly control diabetes mellitus contraindication high dose corticosteroid therapy gastrointestinal disorder abnormality would interfere absorption study drug malignancy diagnose within past 5 year . In exception rule , follow malignancy may include adequately treat : nonmelanomatous skin cancer , cervical carcinoma situ , carcinoma situ breast , low risk endometrial cancer prior systemic therapy ovarian cancer ( e.g . chemotherapy , monoclonal antibody therapy , oral target therapy , hormonal therapy ) prior systemic cytotoxic chemotherapy prior treatment BIBF 1120 angiogenesis inhibitor prior radiotherapy serious illness concomitant nononcological disease neurologic , psychiatric infectious disease laboratory abnormality may increase risk associate study participation study drug administration Women childbearing potential sexually active use highly effective method birth control trial least twelve month end active therapy . pregnancy breast feed psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule active alcohol drug abuse patient unable comply protocol contraindication therapy paclitaxel carboplatin treatment investigational drug participation another clinical trial test drug within past four week start therapy concomitantly trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>